Dihydroorotate dehydrogenase
From Proteopedia
(Difference between revisions)
| Line 10: | Line 10: | ||
== Structural highlights == | == Structural highlights == | ||
| - | <scene name='54/540163/Cv/8'>DHOD FMN/orotate binding site</scene>. The <scene name='54/540163/Cv/9'>inhibitor brequinar binds DHOD in the quinone binding channel</scene>. See also this <scene name='54/540163/Cv/ | + | <scene name='54/540163/Cv/8'>DHOD FMN/orotate binding site</scene>. The <scene name='54/540163/Cv/9'>inhibitor brequinar binds DHOD in the quinone binding channel</scene>. See also this <scene name='54/540163/Cv/11'>representation of brequinar binding</scene>. <ref>PMID:16406782</ref> |
== 3D Structures of dihydroorotate dehydrogenase == | == 3D Structures of dihydroorotate dehydrogenase == | ||
Current revision
| |||||||||||
References
- ↑ Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w. Epub 2013 Mar 20. PMID:23452331 doi:http://dx.doi.org/10.1021/jm301848w
- ↑ Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther. 2009 Feb;8(2):366-75. doi: 10.1158/1535-7163.MCT-08-0664. Epub, 2009 Jan 27. PMID:19174558 doi:http://dx.doi.org/10.1158/1535-7163.MCT-08-0664
- ↑ Hurt DE, Sutton AE, Clardy J. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1610-5. Epub 2006 Jan 10. PMID:16406782 doi:S0960-894X(05)01599-4
